drugset / Trial / NCT06276283
DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)
NaSingle-groupOpen-labelTreatment
Summary
This study tests a combination therapy (i.e., DZD9008 plus bevacizumab) in patients with advanced NSCLC harboring EGFR mutations who have progressed on or after standard of care, which aims to understand whether the combination therapy is safe, how well the combination therapy works, and how the body will process DZD9008 when used in combination with bevacizumab.
Timeline
- Start
- 2023-02-15
- Primary completion
- 2025-12-31
- Completion
- 2026-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | — |
| Subject | Sunvozertinib | Small molecule | 200 mg | — |
| Subject | Sunvozertinib | Small molecule | 300 mg | — |